stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) EBITDA
Maravai LifeSciences Holdings, Inc.'s EBITDA for fiscal 2025 was −$153.1M, compared with −$175.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$58.9M. Over the past ten years it has ranged from −$175.9M (fiscal 2024) to $615.1M (fiscal 2022); the current reading is higher than 25% of that period. Maravai LifeSciences Holdings, Inc. ranks 349th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$153.1M | — |
| FY2024 | −$175.9M | — |
| FY2023 | $20.1M | (96.74%) |
| FY2022 | $615.1M | 4.10% |
| FY2021 | $590.9M | 300.41% |
| FY2020 | $147.6M | 196.28% |
| FY2019 | $49.8M | 23.65% |
| FY2018 | $40.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$1.7M | — |
| Mar 2026 | $10.8M | — |
| Dec 2025 | −$86.5M | — |
| Sep 2025 | $18.5M | — |
| 23 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $243.7M |
| MESO Mesoblast Limited compare | −$57.9M |
| MRVI Maravai LifeSciences Holdings, Inc. | −$58.9M |
| TRVI Trevi Therapeutics, Inc. compare | −$59.4M |
| SRPT Sarepta Therapeutics, Inc. compare | −$101.5M |
| MAZE Maze Therapeutics, Inc. compare | −$143.2M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$164.7M |
| VIR Vir Biotechnology, Inc. compare | −$198.6M |
| REPL Replimune Group, Inc. compare | −$266.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item